Yes—a drug review may reveal that a medicine is causing or worsening memory problems, and some medication-related cognitive problems can improve with treatment. Medication-induced memory problems are changes in memory or thinking linked to drug exposure, and they can resemble dementia. The National Institute on Aging recognizes medication side effects as a possible cause of cognitive impairment. However, reviewing medicines is one part of a broader assessment, not a stand-alone diagnosis.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Which medicines deserve closer review?
- What does the long-term evidence mean?
- How to prepare for a medication review
- Why the review cannot settle the diagnosis
- Do not stop benzodiazepines abruptly
Which medicines deserve closer review?
The National Institute on Aging advises clinicians to examine every prescription, over-the-counter product, and supplement. It specifically highlights anticholinergics, antihistamines, narcotics, sedatives, and benzodiazepines for reassessment. Strong anticholinergic medicines appear in several common categories.
The 2023 American Geriatrics Society Beers Criteria lists examples such as diphenhydramine, amitriptyline, and oxybutynin. It also identifies cumulative anticholinergic exposure as a concern. Benzodiazepines generally increase the risks of cognitive impairment and delirium in adults 65 and older. older adults are more sensitive to these drugs and may process long-acting versions more slowly.
What does the long-term evidence mean?
A large English primary-care study compared 58,769 people diagnosed with dementia with 225,574 matched controls aged 55 or older. High cumulative exposure to strong anticholinergics was associated with 49% higher dementia odds than no exposure. The JAMA Internal Medicine study reported an association, not proof of causation.
Stronger associations appeared with anticholinergic antidepressants, antiparkinson drugs, antipsychotics, bladder antimuscarinics, and antiepileptics. These findings support examining total exposure, especially when someone has used a strong anticholinergic repeatedly or for a long period. They cannot predict an individual's outcome or prove that changing a medicine will reverse established symptoms.
How to prepare for a medication review
Create one complete list rather than relying on memory during the appointment. Include: Bring the list to the clinician evaluating the cognitive symptoms.
Ask which medicines have anticholinergic or sedating effects and whether cumulative exposure may be relevant. A medicine's presence on a caution list does not establish that it caused the symptoms. The review should weigh that possibility while preserving treatment for the condition the medicine was intended to manage.
- Every prescription medicine
- Nonprescription sleep, allergy, and pain products
- Vitamins, herbal products, and other supplements
- Why each product is taken
- When each product was started or changed
Why the review cannot settle the diagnosis
Memory symptoms have several possible explanations. The National Institute on Aging identifies delirium, depression, endocrine or metabolic dysfunction, neurodegenerative disease, and medication effects among the possibilities. A review may uncover a plausible, treatable contributor, but it cannot determine the cause by itself.
Symptoms may require further assessment even when a medicine appears to be involved. The practical goal is to identify exposures worth reassessing and give the clinician a clearer timeline. That information can guide treatment while other possible causes are considered.
Do not stop benzodiazepines abruptly
Stopping a benzodiazepine suddenly after weeks or months of use can cause serious withdrawal. The FDA warns that abrupt discontinuation or overly rapid dose reduction can cause memory problems and potentially life-threatening seizures.
Any taper must follow an individualized clinician plan. Do not change a benzodiazepine dose on your own; contact the prescribing clinician with the complete medication list and symptom timeline.
